Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
1255 daily bars · split adjusted
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Oct 19, 26 | Sulzberger Gabrielle | director | A-Award | 4 @ $1,240.34 | $4.96K |
Daily · Wilder smoothing
| Oct 19, 26 |
| Luciano Juan R |
| director |
| A-Award |
| 13 @ $1,240.34 |
| $15.92K |
| Oct 19, 26 | Fyrwald J Erik | director | A-Award | 8 @ $1,240.34 | $9.92K |
| Oct 19, 26 | Alvarez Ralph | director | A-Award | 10 @ $1,240.34 | $12.42K |
| Sep 21, 26 | Sulzberger Gabrielle | director | A-Award | 4 @ $1,164.89 | $4.96K |
| Sep 21, 26 | Luciano Juan R | director | A-Award | 14 @ $1,164.89 | $15.92K |
| Sep 21, 26 | Fyrwald J Erik | director | A-Award | 9 @ $1,164.89 | $9.92K |
| Sep 21, 26 | Alvarez Ralph | director | A-Award | 11 @ $1,164.89 | $12.42K |
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 62.22 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 81.51 | Oscillator | Sell |
| Williams %R (14) | -25.13 | Oscillator | Neutral |
| MACD (12, 26, 9) | 30.80 (Hist 11.10) | Oscillator | Strong Buy |
| Average Directional Index (14) | 30.19 (+DI 34.4 / -DI 12.8) | Trend | Strong Buy |
| EMA 20 | 1221.57 | MA | Strong Buy |
| SMA 20 | 1204.94 | MA | Strong Buy |
| EMA 50 | 1191.68 | MA | Strong Buy |
| SMA 50 | 1186.60 | MA | Strong Buy |
| SMA 200 | 1084.94 | MA | Strong Buy |
FY2025 · 10-K disclosure
FY2025 · 10-K disclosure
Stock news · updated daily
Novo Nordisk's CagriSema delivers 25% weight loss in women, spotlighting three ETFs for diversified exposure to the sector's growth.
Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.
Business is booming, and the pipeline of new treatments is robust.
A European regulatory endorsement for an oral obesity pill is lifting Eli Lilly (NYSE:LLY | LLY Price Prediction) stock ahead of the rest of the drug group. Eli Lilly stock is up 4% to $1,295.
As of 11:36 AM ET, the Dow Jones Industrial Average (^DJI +0.98%) is up 0.91% to 52,437 as blue-chips outperform, while the S&P 500 (^GSPC +0.46%) has climbed 0.31% to 7,715 and the Nasdaq Composite (^IXIC +0.28%) is up 0.08% to 26,460.
The Dow and Russell 2000 are leading the way today as an oil price pivot sends stocks confidently higher
Eli Lilly just posted 47.7% revenue growth and its weight-loss drugs are reshaping global healthcare, but whether that momentum turns a four-year investment into a windfall or a disappointment depends on factors most investors overlook.
In the latest trading session, Eli Lilly (LLY) closed at $1, marking a -1.33% move from the previous day.
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Aug 5, 2026 | 6.40 | 8.38 | Beat 30.9% | $22.97B |
| Apr 30, 2026 | 6.97 | 8.55 | Beat 22.7% | $19.80B |
| Feb 4, 2026 | 6.91 | 7.54 | Beat 9.1% | $19.29B |
| Oct 30, 2025 | 5.69 | 7.02 | Beat 23.4% | $17.60B |
| Aug 7, 2025 | 5.60 | 6.31 | Beat 12.7% | $15.56B |
| May 1, 2025 | 3.26 | 3.34 | Beat 2.5% | $12.73B |
SEC EDGAR filings · last 12 months
| Form | Filed | Accepted | Document |
|---|---|---|---|
| 4 | Oct 20, 2026 | 2026-10-20 16:36:58 | View |
| 4 | Oct 20, 2026 | 2026-10-20 16:35:55 | View |
| 4 | Oct 20, 2026 | 2026-10-20 16:34:47 | View |
| 4 | Oct 20, 2026 | 2026-10-20 16:32:51 | View |
| SC 13G/A | Oct 19, 2026 | 2026-10-19 15:09:30 | View |
| SC 13D | Oct 16, 2026 | 2026-10-16 16:19:25 | View |
| 3 | Oct 8, 2026 | 2026-10-08 21:39:11 | View |
| 4 | Sep 22, 2026 | 2026-09-22 16:15:24 | View |
| 4 | Sep 22, 2026 | 2026-09-22 16:14:27 | View |
| 4 | Sep 22, 2026 | 2026-09-22 16:12:51 | View |
Proxy statement (DEF 14A) disclosures
TTM vs. 5-year historical average (annual ratios)
| Metric | LLY | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | 42.6x | 63.0x · sector 20.7x | Elevated |
| Forward P/E (FY26E) | 37.4x | EPS est. 34.05 | In line |
| Price / Book | 33.5x | 39.2x | In line |
| Price / Sales | 15.0x | 13.4x | In line |
| EV / EBITDA | 28.7x | 42.0x | Discount |
| Return on equity | 92.6% | — | Top tier |
| Gross margin | 83.4% | 78.9% | In line |
| Debt / Equity | 1.62 | 1.94 | Levered |
| Piotroski / Altman Z | 8/9 | Z 8.78 | Safe zone |
Discounted cash flow model
Current price $1,273.46
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| Oct 21, 26 | Leerink Partners | maintain | Outperform | Outperform |
| Oct 12, 26 | RBC Capital | maintain | Outperform | Outperform |
| Oct 8, 26 | Cantor Fitzgerald | maintain | Overweight | Overweight |
| Oct 7, 26 | Morgan Stanley | maintain | Overweight | Overweight |
| Sep 28, 26 | JP Morgan | maintain | Overweight | Overweight |
| Sep 22, 26 | TD Cowen | maintain | Buy | Buy |
| Sep 18, 26 | Guggenheim | maintain | Buy | Buy |
| Sep 10, 26 | HSBC | maintain | Reduce | Reduce |
| Aug 7, 26 | Truist Securities | maintain | Buy | Buy |